NeoGenomics, Inc. - Common Stock (NQ:NEO)

17.12 -0.81 (-4.52%)

Delayed Quote Updated: 12:08 PM EDT, Oct 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about NeoGenomics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

Testing & Diagnostics Services Stocks Q3 Recap: Benchmarking NeoGenomics (NASDAQ:NEO)

December 05, 2025

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how NeoGenomics (NASDAQ:NEO) and...

Via StockStory

3 Overrated Stocks That Concern Us

December 03, 2025

The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro...

Via StockStory

1 Cash-Burning Stock to Research Further and 2 We Brush Off

November 25, 2025

Rapid spending isn’t always a sign of progress. Some cash-burning businesses fail to convert investments into meaningful competitive advantages, leaving them vulnerable.

Via StockStory

Topics Retirement

NeoGenomics, Fortrea, and Acadia Healthcare Shares Skyrocket, What You Need To Know

November 21, 2025

A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated...

Via StockStory

Topics Artificial Intelligence Economy Stocks

Earnings Scheduled For October 28, 2025 ↗

October 28, 2025

Via Benzinga

1 High-Flying Stock on Our Buy List and 2 We Find Risky

November 16, 2025

Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lofty expectations make them particularly...

Via StockStory

Earnings Scheduled For November 14, 2025 ↗

November 14, 2025

Via Benzinga

1 Small-Cap Stock for Long-Term Investors and 2 We Brush Off

November 09, 2025

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a...

Via StockStory

3 Volatile Stocks We Keep Off Our Radar

November 06, 2025

A highly volatile stock can deliver big gains - or just as easily wipe out a portfolio if things go south. While some investors embrace risk, mistakes can be costly for those who aren’t prepared.

Via StockStory

NeoGenomics to Participate in Upcoming Investor Conferences

November 06, 2025

From NeoGenomics, Inc.

Via Business Wire

The Top 5 Analyst Questions From NeoGenomics’s Q3 Earnings Call

November 04, 2025

NeoGenomics’ third quarter results were met with a negative market reaction, as shares declined following the announcement. Management attributed the quarter’s performance to robust growth in clinical...

Via StockStory

Topics Earnings

NeoGenomics (NEO): Buy, Sell, or Hold Post Q3 Earnings?

November 03, 2025

NeoGenomics trades at $9.78 per share and has stayed right on track with the overall market, gaining 24.7% over the last six months. At the same time, the S&P 500 has returned 21.3%.

Via StockStory

Topics Stocks

NeoGenomics to Present RaDaR ST Bridging Study at ISLB 2025, Demonstrating Reliable MRD Detection Across Solid Tumors

October 30, 2025

From NeoGenomics, Inc.

Via Business Wire

NEO Q3 Deep Dive: Clinical Volume Gains and New Product Launches Shape Outlook

October 29, 2025

Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 11.9% year on year to $187.8 million. The company...

Via StockStory

NeoGenomics (NEO) Q3 2025 Earnings Call Transcript ↗

October 28, 2025

NeoGenomics (NEO) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings Intellectual Property

Why NeoGenomics (NEO) Stock Is Trading Up Today

October 28, 2025

Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) jumped 1.1% in the morning session after it reported third-quarter 2025 results where revenue beat Wall Street's expectations.

Via StockStory

Topics World Trade

NeoGenomics Inc (NASDAQ:NEO) Surpasses Q3 Revenue Estimates as Clinical Testing Drives Growth ↗

October 28, 2025

NeoGenomics Q3 2025 earnings beat revenue estimates with 11.9% growth. Clinical test volume surged 15%, driving a 5.4% pre-market stock rally.

Via Chartmill

Topics Earnings

NeoGenomics’s (NASDAQ:NEO) Q3 Sales Top Estimates, Stock Soars

October 28, 2025

Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) beat Wall Street’s revenue expectations in Q3 CY2025, with sales up 11.9% year on year to $187.8 million. The company expects the full...

Via StockStory

NeoGenomics Reports Third Quarter 2025 Results

October 28, 2025

From NeoGenomics, Inc.

Via Business Wire

NeoGenomics (NEO) Reports Earnings Tomorrow: What To Expect

October 26, 2025

Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) will be reporting results this Tuesday before market open. Here’s what to expect.

Via StockStory

Topics Artificial Intelligence

3 Healthcare Stocks Walking a Fine Line

October 24, 2025

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But financial performance has lagged recently as players offloaded surplus COVID...

Via StockStory

Topics Stocks

3 Unprofitable Stocks with Open Questions

October 20, 2025

Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure.

Via StockStory

Federal Reserve Signals Further Rate Cuts Amidst Worsening Labor Market and Divided Opinions

October 14, 2025

Washington D.C. – The Federal Reserve has sent clear signals of a continued dovish pivot, with Chair Jerome Powell indicating the likelihood of two additional quarter-point interest rate cuts before...

Via MarketMinute

Topics Artificial Intelligence Bonds Credit Cards

NeoGenomics to Highlight RaDaR ST MRD Assay at ESMO Congress 2025

October 14, 2025

From NeoGenomics, Inc.

Via Business Wire

NeoGenomics to Report Third Quarter 2025 Financial Results on October 28, 2025

October 07, 2025

From NeoGenomics, Inc.

Via Business Wire

3 Russell 2000 Stocks We Approach with Caution

October 07, 2025

The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher...

Via StockStory

agilon health, Tandem Diabetes, NeoGenomics, Hims & Hers Health, and Oscar Health Stocks Trade Up, What You Need To Know

October 02, 2025

A number of stocks jumped in the afternoon session after news of a new government prescription drug policy and a landmark deal with Pfizer eased investor concerns over stricter pricing regulations.

Via StockStory

Topics World Trade

3 Cash-Burning Stocks We’re Skeptical Of

September 19, 2025

While some companies burn cash to fuel expansion, others struggle to turn spending into sustainable growth. A high cash burn rate without a strong balance sheet can leave investors exposed to...

Via StockStory

NeoGenomics Stock In A Range-Bound Matrix, Weakness Likely Until 2026 ↗

September 17, 2025

Adhishthana.com analysis shows NeoGenomics has chosen the blue pill, consolidation likely to last until August 2026.

Via Benzinga

Anchored at 4%: Why the Steady 10-Year Treasury Yield is Key to Unlocking the Fed's Stimulus Power

September 15, 2025

The U.S. financial markets are currently at a critical juncture, with the stability of the 10-year Treasury yield hovering steadfastly around the 4% mark. This apparent calm in long-term borrowing...

Via MarketMinute

Topics Artificial Intelligence Bonds Economy

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.